21.62
0.18 (0.84%)
| Previous Close | 21.44 |
| Open | 21.31 |
| Volume | 686,803 |
| Avg. Volume (3M) | 1,199,274 |
| Market Cap | 1,586,408,576 |
| Price / Sales | 6.47 |
| Price / Book | 4.02 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 |
| Profit Margin | -83.39% |
| Operating Margin (TTM) | -85.45% |
| Diluted EPS (TTM) | -2.63 |
| Quarterly Revenue Growth (YOY) | 62.70% |
| Total Debt/Equity (MRQ) | 31.15% |
| Current Ratio (MRQ) | 3.45 |
| Operating Cash Flow (TTM) | 25.97 M |
| Levered Free Cash Flow (TTM) | -17.73 M |
| Return on Assets (TTM) | -16.27% |
| Return on Equity (TTM) | -43.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Mixed |
| Health Information Services (Global) | Bearish | Mixed | |
| Stock | Schrodinger, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.30 |
|
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 2.58% |
| % Held by Institutions | 101.84% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gates Foundation Trust | 31 Mar 2025 | 6,981,664 |
| 52 Weeks Range | ||
| Median | 32.00 (48.01%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Keybanc | 16 Apr 2025 | 32.00 (48.01%) | Buy | 25.21 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHODAKEWITZ JEFFREY | 21.05 | - | 5,997 | 126,237 |
| FRIESNER RICHARD | 21.05 | - | 5,997 | 126,237 |
| GINSBERG GARY L | 21.05 | - | 5,997 | 126,237 |
| KAPELLER-LIBERMANN ROSANA | 21.05 | - | 5,997 | 126,237 |
| LYNTON MICHAEL | 21.05 | - | 5,997 | 126,237 |
| OBEROI ARUN | 21.05 | - | 5,997 | 126,237 |
| SENDER GARY | 21.05 | - | 5,997 | 126,237 |
| THORNBERRY NANCY | 21.05 | - | 5,997 | 126,237 |
| VAN KRALINGEN BRIDGET A | 21.05 | - | 1,499 | 31,554 |
| Aggregate Net Quantity | 49,475 | |||
| Aggregate Net Value ($) | 1,041,449 | |||
| Aggregate Avg. Buy ($) | 21.05 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FRIESNER RICHARD | Director | 18 Jun 2025 | Acquired (+) | 5,997 | 21.05 | 126,237 |
| OBEROI ARUN | Director | 18 Jun 2025 | Acquired (+) | 5,997 | 21.05 | 126,237 |
| GINSBERG GARY L | Director | 18 Jun 2025 | Acquired (+) | 5,997 | 21.05 | 126,237 |
| KAPELLER-LIBERMANN ROSANA | Director | 18 Jun 2025 | Acquired (+) | 5,997 | 21.05 | 126,237 |
| THORNBERRY NANCY | Director | 18 Jun 2025 | Acquired (+) | 5,997 | 21.05 | 126,237 |
| VAN KRALINGEN BRIDGET A | Director | 18 Jun 2025 | Acquired (+) | 1,499 | 21.05 | 31,554 |
| LYNTON MICHAEL | Director | 18 Jun 2025 | Acquired (+) | 5,997 | 21.05 | 126,237 |
| SENDER GARY | Director | 18 Jun 2025 | Acquired (+) | 5,997 | 21.05 | 126,237 |
| CHODAKEWITZ JEFFREY | Director | 18 Jun 2025 | Acquired (+) | 5,997 | 21.05 | 126,237 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |